--- title: "FY2028 EPS Estimates for MediciNova Lowered by HC Wainwright" type: "News" locale: "en" url: "https://longbridge.com/en/news/296060265.md" description: "HC Wainwright lowered MediciNova's FY2028 EPS estimate to $0.28 from $0.29, while setting FY2029 and FY2030 estimates at $1.87 and $3.00 respectively. Weiss Ratings downgraded the stock to 'sell (e+)'. Institutional investors including State Street and Goldman Sachs increased their stakes in Q4. MediciNova recently reported quarterly earnings of ($0.05), beating consensus estimates." datetime: "2026-08-17T05:42:53.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296060265.md) - [en](https://longbridge.com/en/news/296060265.md) - [zh-HK](https://longbridge.com/zh-HK/news/296060265.md) generator: "portal-rs" --- # FY2028 EPS Estimates for MediciNova Lowered by HC Wainwright MediciNova, Inc. (NASDAQ:MNOV - Free Report) - HC Wainwright cut their FY2028 earnings per share (EPS) estimates for MediciNova in a report issued on Friday, August 14th. HC Wainwright analyst L. Egana-Gorrono now expects that the biopharmaceutical company will post earnings of $0.28 per share for the year, down from their previous estimate of $0.29. The consensus estimate for MediciNova's current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for MediciNova's FY2029 earnings at $1.87 EPS and FY2030 earnings at $3.00 EPS. MNOV has been the subject of several other reports. Weiss Ratings lowered MediciNova from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, August 11th. D. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of MediciNova in a research report on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, MediciNova has an average rating of "Moderate Buy" and a consensus target price of $8.33. **Read Our Latest Report on MNOV** ## MediciNova Stock Performance MediciNova stock opened at $1.31 on Monday. MediciNova has a 52 week low of $1.17 and a 52 week high of $1.96. The stock has a market cap of $64.48 million, a P/E ratio of -6.24 and a beta of 0.63. The stock has a 50 day moving average of $1.34 and a 200-day moving average of $1.41. MediciNova (NASDAQ:MNOV - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. MediciNova had a negative return on equity of 26.51% and a negative net margin of 1,168.70%.The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.07 million. ## Institutional Inflows and Outflows A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp increased its position in MediciNova by 10.9% in the fourth quarter. State Street Corp now owns 193,698 shares of the biopharmaceutical company's stock worth $254,000 after buying an additional 19,100 shares during the period. Jane Street Group LLC bought a new stake in MediciNova in the fourth quarter valued at $214,000. Goldman Sachs Group Inc. acquired a new position in shares of MediciNova during the fourth quarter valued at $35,000. Citadel Advisors LLC acquired a new position in shares of MediciNova during the third quarter valued at $92,000. Finally, StoneX Group Inc. bought a new position in shares of MediciNova during the fourth quarter worth about $25,000. Institutional investors and hedge funds own 9.90% of the company's stock. ## MediciNova Company Profile (Get Free Report) MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets. The company's leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness. ## Read More - Five stocks we like better than MediciNova - The Metals Company’s Big Bet Now Comes Down to a License - OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings - Meta and Tesla Are Rebounding From Oversold Levels—Now What? - AMG’s Alternatives Boom Powers Record Growth *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in MediciNova Right Now? Before you consider MediciNova, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list. While MediciNova currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [MNOV.US](https://longbridge.com/en/quote/MNOV.US.md) - [STT.US](https://longbridge.com/en/quote/STT.US.md) - [GS.US](https://longbridge.com/en/quote/GS.US.md) - [SNEX.US](https://longbridge.com/en/quote/SNEX.US.md) - [TMC.US](https://longbridge.com/en/quote/TMC.US.md) - [OSW.US](https://longbridge.com/en/quote/OSW.US.md) - [META.US](https://longbridge.com/en/quote/META.US.md) - [TSLA.US](https://longbridge.com/en/quote/TSLA.US.md) - [AMG.US](https://longbridge.com/en/quote/AMG.US.md) - [4875.JP](https://longbridge.com/en/quote/4875.JP.md) - [SPIN.US](https://longbridge.com/en/quote/SPIN.US.md) - [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md) - [TMCWW.US](https://longbridge.com/en/quote/TMCWW.US.md) - [MGRE.US](https://longbridge.com/en/quote/MGRE.US.md) ## Related News & Research - [FY2027 EPS Estimate for Movado Group Boosted by Analyst](https://longbridge.com/en/news/297316950.md) - [Flex Ltd. $FLEX Shares Sold by Raiffeisen Bank International AG](https://longbridge.com/en/news/298024127.md) - [Goldman Sachs lifts SBO voting rights stake to 4.36% from 3.99%](https://longbridge.com/en/news/297479355.md) - [Public Employees Retirement System of Ohio Makes New $21.28 Million Investment in Sun Communities, Inc. $SUI](https://longbridge.com/en/news/297421282.md) - [Navellier & Associates Inc. Sells 223,975 Shares of Coeur Mining, Inc. $CDE](https://longbridge.com/en/news/297421945.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**